NanoViricides began a Phase II trial of NV-387 oral gummies for mpox, enrolling the first patients in the Democratic Republic of Congo.
No clinical results have been presented; the study is designed to generate future safety and efficacy readouts.
The trial compares NV-387 with standard of care in patients with clinical mpox and confirmed or presumptive infection, using an adaptive randomized open-label design.
The move targets a market with no approved mpox treatment, following prior tecovirimat trials that failed to show benefit in mpox.
The company positioned the program as a potential pathway toward U.S. pandemic-response procurement if Phase II results support further development.
NNVC•
